Biotech Small-Cap Fundamental Analysis Healthcare Score Distribution Cash Runway Pre-Revenue Data Analysis 2026

We Scored 313 Small-Cap Biotechs — 80% Score Below 50. Here's Why That's Correct.

May 28, 2026

Of 313 small-cap biotechs in our universe, 80% score below 50 and only 7% score 70+. That looks like a model failure. It isn't — the screen is correctly flagging pre-revenue binary-outcome risk. The data, the 7% that pass, and what it means for your watchlist.

We score 2,200+ US small-cap stocks (market cap <$2B) every week on eight fundamentals: revenue growth, gross margin, cash runway, debt-to-equity, P/S ratio, Rule of 40, insider ownership, and 12-month share dilution. One sub-industry breaks the model harder than any other.

Of 313 small-cap biotechs in our universe, 80.2% score below 50. Average score: 37.6. More than half (54%) have less than 12 months of cash runway. Nearly half (49%) are pre-revenue. Only 7.3% score 70 or above.

Compare that to the rest of the small-cap universe: Technology averages 58.3, Communication Services 61.7, Industrials 53.9. Even other Healthcare sub-industries score reasonably: Drug Manufacturers (Specialty) average 56.7, Health Information Services 62.9. It is biotech specifically — not healthcare broadly — that breaks the screen.

That seems like a flaw. It is not. Here is why.

The Distribution: All Healthcare Sub-Industries

Below: every Healthcare sub-industry in our small-cap universe with 10 or more names, ranked by what percentage scores below 50.

Sub-Industry	Names	Avg Score	% Below 50	% 70+	% <12mo Runway	% Pre-Revenue
Biotechnology	313	37.6	80.2%	7.3%	54.0%	48.9%
Drug Manufacturers (Specialty)	33	56.7	39.4%	24.2%	15.2%	9.1%
Medical Instruments & Supplies	20	53.0	30.0%	10.0%	35.0%	15.0%
Medical Devices	69	55.3	29.0%	17.4%	29.0%	1.4%
Medical Care Facilities	27	56.5	25.9%	11.1%	11.1%	7.4%
Diagnostics & Research	15	57.5	13.3%	6.7%	26.7%	0.0%
Health Information Services	28	62.9	10.7%	25.0%	10.7%	3.6%

Biotechnology is not just slightly worse. It is structurally different. The gap between biotechs (80.2%) and the next-worst Healthcare sub-industry (Drug Manufacturers Specialty at 39.4%) is wider than the gap between Drug Manufacturers and Communication Services (11.6%).

Why The Distribution Looks This Way

Clinical-stage biotechs are not bad businesses. They are not businesses at all yet — they are long-dated R&D options.

Our eight metrics were designed to evaluate operating businesses. Five of them break for pre-revenue biotechs:

Revenue growth — undefined when revenue is zero. Either logged as 'pre-revenue' (49% of biotechs) or distorted by tiny base effects.
Gross margin — undefined or negative because there is no commercial product yet.
Rule of 40 — combines growth and FCF margin. Both inputs are broken pre-commercial.
P/S ratio — meaningless when sales are essentially zero.
Cash runway — this one is informative, and it is exactly where the screen flags the problem. 54% of small-cap biotechs have under 12 months of runway. That is not a model error. That is the actual business.

The other three metrics — debt/equity, insider ownership, dilution — work fine for biotechs. Insider ownership is often high in early-stage names (founder-led, VC-overhang); dilution is almost always elevated (clinical biotechs raise every 12-24 months); debt is usually low (banks don't lend to pre-FDA-approval pipelines).

Net effect: a model designed for operating businesses will systematically score pre-revenue binary-outcome companies low. That is not a flaw in the model — it is a feature. The model is telling you, correctly, that the company is not yet an operating business and the binary-outcome risk dominates the fundamentals.

The 7%: Biotechs That DO Score 70+

The 23 biotechs that score 70+ have something in common: they ship a commercial product. Either FDA-approved drug, regulated medical device with collected revenue, or upstream platform revenue from partnership milestones. The model isn't excluding biotech — it is excluding clinical-stage biotech. Pre-commercial is the killer, not the sector.

Here are the top six small-cap biotechs ranked by score as of May 24:

CGEN — Compugen Ltd.

Score: 89.7 (EXCELLENT) | Market cap: $250M | Revenue YoY: +161% | Runway: net cash

Computational immuno-oncology platform — pipeline progressed through 2025-2026 with milestone payments from a Bristol-Myers collaboration. Revenue YoY +161% reflects the milestone-payment structure, runway effectively net-cash. → Full CGEN score card

VRCA — Verrica Pharmaceuticals Inc.

Score: 88.1 (EXCELLENT) | Market cap: $109M | Revenue YoY: +370% | Runway: 21mo

FDA-approved dermatology product (YCANTH for molluscum) — commercial-stage with revenue ramping off the 2024 launch. Revenue +370% YoY, Rule of 40 >300. Cash runway ~20 months. → Full VRCA score card

CRMD — CorMedix Inc.

Score: 87.7 (EXCELLENT) | Market cap: $620M | Revenue YoY: +617% | Runway: net cash

FDA-approved DefenCath (catheter-lock-solution for hemodialysis patients) — commercial-stage, first full year of sales. Revenue +617% YoY off small base, net cash, Rule of 40 north of 600. → Full CRMD score card

RIGL — Rigel Pharmaceuticals, Inc.

Score: 87.0 (EXCELLENT) | Market cap: $547M | Revenue YoY: +64% | Runway: net cash

Commercial-stage hematology — TAVALISSE and REZLIDHIA franchises generating real revenue + REZLIDHIA royalty stream. Revenue +64% YoY, profitable, net cash. → Full RIGL score card

NAGE — Niagen Bioscience, Inc.

Score: 84.5 (EXCELLENT) | Market cap: $393M | Revenue YoY: +30% | Runway: net cash

Nicotinamide riboside consumer + pharma franchise (Niagen) — already cash-generative, mid-growth at +30% YoY with positive Rule of 40 ~41, net cash. The contrarian biotech: it looks more like a specialty consumer brand than a clinical-stage biotech. → Full NAGE score card

ZVRA — Zevra Therapeutics, Inc.

Score: 82.7 (EXCELLENT) | Market cap: $594M | Revenue YoY: +351% | Runway: 469mo

Commercial-stage rare-disease pharma — OLPRUVA (urea cycle disorders) plus a sodium-channel blocker franchise. Revenue +351% YoY, runway ~39 years (yes, really — it's a small-share-count company with a large recent raise). → Full ZVRA score card

What Failure Looks Like: The Bottom 4

On the other tail: four biotechs at the bottom of our universe, scoring under 15. The common pattern is identical — pre-revenue or near-zero revenue, runway under 6 months, facing a forced raise or restructuring in the next two quarters. The model does not predict FDA outcomes. It does predict cash-rebuild timelines, and these are the names where the timeline is already running out.

HUMA — Humacyte, Inc.

Score: 8.0 (CRITICAL) | Market cap: $205M | Revenue YoY: pre-rev | Runway: 6mo

Humacyte (bioengineered vascular conduit) — pre-revenue, no current revenue line, runway under 6 months. Either raises soon or restructures. → Full HUMA score card

INO — Inovio Pharmaceuticals, Inc.

Score: 8.9 (CRITICAL) | Market cap: $93M | Revenue YoY: -70% | Runway: 6mo

Inovio (DNA-based vaccine platform) — revenue collapsed -70% YoY as Covid-era pipeline wound down. Rule of 40 reading is mathematical artefact of near-zero revenue base. ~6 months runway. → Full INO score card

ACHV — Achieve Life Sciences, Inc.

Score: 12.2 (CRITICAL) | Market cap: $233M | Revenue YoY: pre-rev | Runway: 5mo

Achieve Life Sciences (cytisinicline for smoking cessation) — pre-revenue, awaiting FDA decision. ~5 months runway. Pure binary FDA bet. → Full ACHV score card

MSLE — Satellos Bioscience Inc.

Score: 13.0 (CRITICAL) | Market cap: $176M | Revenue YoY: pre-rev | Runway: 5mo

Satellos Bioscience (Duchenne muscular dystrophy pipeline) — pre-revenue, Phase 1/2 stage. ~5 months runway. Classic clinical-stage burn profile. → Full MSLE score card

What This Means For Your Watchlist

Three practical takeaways:

1. The biotech score distribution is a feature, not a bug. A low score on a pre-revenue clinical biotech is the model telling you that the binary-outcome risk dominates the fundamentals. If you want to own clinical-stage biotech, you have to underwrite the science separately — the fundamental screen cannot do it for you.

2. Score-based filtering is most useful for commercial-stage biotechs. Of the 313 biotechs in our universe, 23 score 70+ and 51% of those have FDA-approved revenue-generating products. The screen captures the operating-business transition, which is the moment when biotech becomes investable by the same rules as any other small-cap.

3. Cross-reference with cash runway before any biotech position. Even the 'good' biotech names need this check. A SOLID score on a biotech with 8 months of runway is a different position than a SOLID score on an industrial with 10 years of cash flow. Sizing should reflect that.

For the names that pass — including the six above — see the individual score cards for current metrics, peer comparisons, and the eight underlying fundamental readings.

How We Scored

Our model rates every US small-cap stock (market cap <$2B) across eight fundamentals: revenue growth, gross margin, cash runway, debt/equity, P/S ratio, Rule of 40, insider ownership, and 12-month share dilution. Sector-adjusted where appropriate. Scores refresh weekly. See methodology or browse all small-cap biotech stocks.

Related Coverage

Data as of May 28, 2026. Universe: 2,200+ US small-cap stocks <$2B market cap. Scores refreshed weekly. Not investment advice.